临床试验/NCT05951777

NCT05951777招募中2 期

Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

Hope Biosciences LLC4 个研究点分布在 1 个国家目标入组 51 人开始时间: 2024年4月16日最近更新: 2026年7月15日

适应症

干预措施

试验速览

阶段: 2 期
状态: 招募中
发起方: Hope Biosciences LLC
入组人数: 51
试验地点: 4
主要终点: Absolute Neutrophils

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The global objective of this study is to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure, neurocognitive/functional outcomes, and neuroinflammation after traumatic brain injury.

详细描述

This study is a prospective, randomized, double-blind, placebo-controlled Phase 2a study of three infusions of autologous HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) (2 x 10^8 total cells per dose) administered over a 6 week period with 14 day intervals between infusions. Subjects will be monitored and assessed for infusion related toxicity for at least 1 hour after the infusion and by telephone 24hr. after each infusion. Safety assessments will be conducted at the study follow-up clinic visits 6 and 12 months, and 2 years (telephone call) after the last HB-adMSC (Hope Biosciences adipose-derived mesenchymal stem cells) infusion, or more frequently if infusion related adverse events are suspected.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围: 18 Years 至 55 Years（Adult）
性别: All
接受健康志愿者: 否

入选标准

•Adults between 18 and 55 years of age.
•Documented functional neurological damage to the central nervous system from blunt force head trauma unlikely to improve with present standard of care approaches.
•A Glasgow Outcome Scale-Extended (GOS-E) score > 2 and ≤
•Onset or diagnosis of the injury or disease process greater than 6 months and ≤ 20 years.
•Ability to obtain consent from the subject or their legally authorized representative (LAR).
•Ability to verbally communicate in English or Spanish (required for validated neurocognitive outcome testing).

排除标准

•Known history of:
•intellectual deficiency or uncontrolled psychiatric conditions likely to invalidate our ability to assess changes in cognition or behavior, or at the discretion of the PI,
•recently treated infection,
•renal disease or altered renal function (screening eGFR < 60 mL/min/1.73m2),
•hepatic disease or altered liver function (screening SGPT > 150 U/L or T. Bilirubin >1.3 mg/dL),
•immunosuppression (screening WBC < 3, 000 cells/ml),
•Positive infectious disease tests including HIV, Hep. B, Hep. C., and Syphilis,
•chemical or ETOH dependency that in the opinion of the investigator would preclude enrollment/participation in the study,
•acute or chronic lung disease requiring significant medication/oxygen supplementation,
•bleeding disorders, thrombocytopenia, including immune-mediated heparin-induced thrombocytopenia,
•known sensitivity to heparin, Lovenox, and pork products,
•individuals with mechanical prosthetic heart valves,
•individuals who have received a stem cell treatment, gene or cellular therapy.
•Normal brain CT/MRI exam.
•Planned epidural or spinal anesthesia, or undergoing spinal puncture, complete spinal cord injury.
•Diagnosed with a genetic or metabolic disorder related to the neurologic condition.
•Other acute or chronic medical conditions that, in the opinion of the investigator, may increase the risks associated with study participation.
•For women of childbearing potential, a positive pregnancy test at the screening visit or, for both women and men, unwillingness to comply with acceptable methods of birth control during the study.
•Concurrent participation in interventional drug or device study.
•Inability to undergo the diagnostic tests (PET/DT-MRI) or unwilling/unable to cooperate with the diagnostic tests and outcome assessments.
•Metal implants including baclofen pumps that would preclude DT-MRI.
•Unwilling or unable to return for the follow-up study visits.
•Uncorrectable vision impairment that will prevent completion of neurocognitive tests require visual processing.

研究组 & 干预措施

Treatment

Experimental

Autologous Adipose Derived Mesenchymal Stem Cells

干预措施: Autologous HB-adMSCs (Biological)

Placebo

Placebo Comparator

Normal Saline

干预措施: Normal Saline (Drug)

结局指标

主要结局

Absolute Neutrophils

时间窗: Week 0 (Infusion 1), change from week 0 (Infusion 1) at week 2 (Infusion 2), change from week 0 (Infusion 1) at week 4 (Infusion 3), change from week 0 (Infusion 1) at 6 months post-infusion, change from week 0 (Infusion 1) at 1 year post-infusion

clinical evaluation of absolute neutrophils in blood (x 10\^3/uL)

Eosinophils

clinical evaluation of eosinophils in blood (%)

Basophils

clinical evaluation of basophils in blood (%)

Absolute lymphocytes

clinical evaluation of absolute lymphocytes in blood (x 10\^3/uL)

Absolute monocytes

clinical evaluation of absolute monocytes in blood (x 10\^3/uL)

Absolute eosinophils

clinical evaluation of absolute eosinophils in blood (x 10\^3/uL)

Mean corpuscular volume

clinical evaluation of mean corpuscular volume (MCV) in blood (fL)

Glucose

clinical lab evaluation of level of glucose in the blood (mg/dL)

Calcium

clinical lab evaluation of level of calcium in the blood (mg/dL) clinical lab evaluation of level of calcium in the blood (mg/dL) clinical lab evaluation of level of calcium in the blood (mg/dL)

Albumin

clinical lab evaluation of level of albumin in the blood (g/dL)

Total Protein

clinical lab evaluation of total protein in the blood (g/dL)

Sodium

clinical lab evaluation of total sodium in the blood (mmol/L)

Total Bilirubin

clinical evaluation of total bilirubin in blood (mg/dL)

White blood cell

clinical evaluation of white blood cells (WBC) in blood (x 10\^3/uL)

Total carbon dioxide

clinical lab evaluation of total carbon dioxide in the blood (mmol/L)

Potassium

clinical lab evaluation of potassium in the blood (mmol/L)

Chloride

clinical lab evaluation of chloride in the blood (mmol/L)

BUN (blood urea nitrogen)

clinical evaluation of blood urea nitrogen (BUN) (mg/dL)

Creatinine

clinical evaluation of creatinine in blood (mg/dL

Alkaline phosphatase

clinical evaluation of alkaline phosphatase (ALP) in blood (IU/L)

Alanine aminotransferase

clinical evaluation of alanine aminotransferase (ALT) in blood (IU/L)

Aspartate aminotransferase

clinical evaluation of aspartate aminotransferase (AST) in blood (IU/L)

Red blood cell

clinical evaluation of red blood cells (RBC) in blood (x 10\^6/uL)

Hemoglobin

clinical evaluation of hemoglobin in blood (g/dL)

Hematocrit

clinical evaluation of hematocrit in blood (%)

Mean corpuscular hemoglobin

clinical evaluation of mean corpuscular hemoglobin (MCH) in blood (pg)

Mean corpuscular hemoglobin concentration

clinical evaluation of mean corpuscular hemoglobin concentration (MCHC) in blood (g/dL)

Red cell distribution width

clinical evaluation of red cell distribution width (RDW) in blood (%)

Neutrophils

clinical evaluation of neutrophils in blood (%)

Lymphocytes

clinical evaluation of lymphocytes in blood (%)

Monocytes

clinical evaluation of monocytes in blood (%)

Absolute basophils

clinical evaluation of absolute basophils in blood (x 10\^3/uL)

Immature Granulocytes

clinical evaluation of immature granulocytes in blood (%)

Absolute Immature Granulocytes

clinical evaluation of absolute immature granulocytes in blood (x 10\^3/uL)

Platelets

clinical evaluation of platelets in blood (x 10\^3/uL)

Prothrombin Time

clinical evaluation of time for blood to coagulate (seconds)

INR (international normalized ratio)

clinical evaluation of international normalized ratio of blood coagulation (no unit)

Urine Pregnancy (if applicable)

clinical evaluation of human chorionic gonadotropin (hCG) in urine (positive/negative)

次要结局

Whole brain MRI (Magnetic resonance imaging)(Baseline, change from baseline at 6 months post-infusion)
PET/DT-MRI (positron emission tomography/Diffusion tensor-Magnetic resonance imaging)(Baseline, change from baseline at 6 months post-infusion)
Glasgow Outcome Scale - Extended(Baseline, change from baseline at 6 months post-infusion, change from baseline at 1 year post-infusion)
Disability Rating Scale(Baseline, change from baseline at 6 months post-infusion, change from baseline at 1 year post-infusion)
Behavior Rating of Executive Functions-Adult(Baseline, change from baseline at 6 months post-infusion, change from baseline at 1 year post-infusion)
TBI (Traumatic Brain Injury) Quality of Life Questionnaires(Baseline, change from baseline at 6 months post-infusion, change from baseline at 1 year post-infusion)
Brief Symptom Inventory 18(Baseline, change from baseline at 6 months post-infusion, change from baseline at 1 year post-infusion)
NIH Toolbox - Pattern Comparison Processing Speed Test(Baseline, change from baseline at 6 months post-infusion, change from baseline at 1 year post-infusion)
NIH Toolbox - Dimensional Change Card Sort Test(Baseline, change from baseline at 6 months post-infusion, change from baseline at 1 year post-infusion)
NIH Toolbox - Picture Vocabulary Test(Baseline, change from baseline at 6 months post-infusion, change from baseline at 1 year post-infusion)
NIH Toolbox - List Sorting Working Memory Test(Baseline, change from baseline at 6 months post-infusion, change from baseline at 1 year post-infusion)
NIH Toolbox - Flanker Inhibitory Control and Attention Test(Baseline, change from baseline at 6 months post-infusion, change from baseline at 1 year post-infusion)
NIH Toolbox - 9-hole Pegboard Dexterity Test(Baseline, change from baseline at 6 months post-infusion, change from baseline at 1 year post-infusion)
Rey Auditory Verbal Learning Test(Baseline, change from baseline at 6 months post-infusion, change from baseline at 1 year post-infusion)
Verbal Fluency(Baseline, change from baseline at 6 months post-infusion, change from baseline at 1 year post-infusion)
Interleukin 10(Baseline imaging (visit #2), change from baseline at 6 months post-infusion, change from baseline 1 year post-infusion)
Wechsler Adult Intelligence Scale - IV: Processing Speed Index(Baseline, change from baseline at 6 months post-infusion, change from baseline at 1 year post-infusion)
Plasma cytokines(Baseline imaging (visit #2), change from baseline at 6 months post-infusion, change from baseline 1 year post-infusion)
Interleukin 1-alpha(Baseline imaging (visit #2), change from baseline at 6 months post-infusion, change from baseline 1 year post-infusion)
Interleukin 4(Baseline imaging (visit #2), change from baseline at 6 months post-infusion, change from baseline 1 year post-infusion)
Tumor necrosis factor alpha(Baseline imaging (visit #2), change from baseline at 6 months post-infusion, change from baseline 1 year post-infusion)
Interleukin 6(Baseline imaging (visit #2), change from baseline at 6 months post-infusion, change from baseline 1 year post-infusion)
Albumin(Baseline imaging (visit #2), change from baseline at 6 months post-infusion, change from baseline 1 year post-infusion)

研究者

发起方

Hope Biosciences LLC

申办方类型

Industry

责任方

Sponsor

研究点 (4)

Loading locations...

相似试验

招募中

1 期

Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney InjuryAcute Kidney Injury

NCT06654193Hope Biosciences LLC70

撤回

1 期

Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI)Ischemia Reperfusion Injury

NCT04388761Tambi Jarmi

已完成

1 期

Adipose Stem Cells for Traumatic Spinal Cord InjurySpinal Cord InjuriesParalysis

NCT03308565Mohamad Bydon10

已完成

1 期

Outcomes of Adipose Derived Mesenchymal Stem Cells on Sexual Hormone DeficiencyHormone Deficiency

NCT03346967Vinmec Research Institute of Stem Cell and Gene Technology30

已完成

早期 1 期

Experimental Autologous Mesenchymal Stem Cell Therapy in Treatment of Chronic Autoimmune UrticariaAutoimmune DiseasesImmune System DiseasesSkin DiseasesUrticaria

NCT02824393Celal Bayar University10